The β-2 agonist debate: is there still a problem?

@article{Patel2013TheA,
  title={The β-2 agonist debate: is there still a problem?},
  author={Mitesh Patel and Philippa Shirtcliffe and Richard Beasley},
  journal={Current opinion in allergy and clinical immunology},
  year={2013},
  volume={13 1},
  pages={58-62}
}
PURPOSE OF REVIEW To present an evidence-based review of the US Food and Drug Administration (FDA) recommendations for long-acting β agonist (LABA) use in asthma. RECENT FINDINGS The FDA recommendation contraindicating the use of LABAs without a concomitant asthma-controller medication such as an inhaled corticosteroid (ICS) is supported, with the caveat that concomitant use of an asthma-controller medication applies only to ICS therapy and not other asthma controller medications (such as… CONTINUE READING